english.prescrire.org > Prescrire International > N°238 - June 2022

n°238

June 2022

Issue Contents
Editorial

Free  Not that common

p.143

Marketing Authorisations

Nirmatrelvir + ritonavir (Paxlovid°) in covid-19

p.145-148
For certain patients at risk of developing severe disease

NVX-CoV2373 (Nuvaxovid°) in the prevention of covid-19 in adults

p.148-149
Effective for at least 3 months, but no proven efficacy against the Omicron variant

Filgotinib (Jyseleca°) in rheumatoid arthritis

p.149-150

Esketamine (Spravato°) in depression with a high risk of suicide

p.150-151

Pembrolizumab (Keytruda°) as first-line treatment for certain metastatic colorectal cancers

p.152

Peanut protein (Palforzia°) for oral desensitisation

p.153-156
Increased incidence of allergic reactions in everyday life

Editor's opinion. Strategic choices

p.154

Dapagliflozin: withdrawal of European marketing authorisation for type 1 diabetes

p.156

Adverse Effects

Messenger RNA covid-19 vaccines tozinameran (Comirnaty°) and elasomeran (Spikevax°) during pregnancy

p.157-159

Immune checkpoint inhibitor immunostimulants: myasthenia gravis

p.159

Free  Hydroxycarbamide: interstitial lung disease

p.160

Paracetamol: beware of liver injury in case of alcohol use or fasting

p.161

Statins: exacerbation of diabetes (continued)

p.161

Common stem: -tinib

p.162

Common stem: -imod

p.163

Outlook

Clinical study reports produced by drug companies: complete access should be guaranteed

p.164-165

The role of the European Medicines Agency in preparedness for public health crises

p.165

"Real-world data": value remains to be elucidated

p.166

Free  The finances of Association Mieux Prescrire: 2021 annual report

p.167

Masthead

Free  Masthead

p.142

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe